Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers.
biomarkers
breast cancer
cancer
gastrointestinal tract cancer
head and neck cancer
immunoediting
immunotherapy
lung cancer
melanoma
renal cell carcinoma
urothelial cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
received:
11
10
2019
revised:
29
10
2019
accepted:
30
10
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
31
3
2020
Statut:
epublish
Résumé
Immunotherapy has become the standard-of-care in many solid tumors. Despite the significant recent achievements in the diagnosis and treatment of cancer, several issues related to patients' selection for immunotherapy remain unsolved. Multiple lines of evidence suggest that, in this setting, the vision of a single biomarker is somewhat naïve and imprecise, given that immunotherapy does not follow the rules that we have experienced in the past for targeted therapies. On the other hand, additional immune-related biomarkers that are reliable in real-life clinical practice remain to be identified. Recently, the immune-checkpoint blockade has been approved in the US irrespective of the tumor site of origin. Further histology-agnostic approvals, coupled with with tumor-specific companion diagnostics and guidelines, are expected in this field. In addition, immune-related biomarkers can also have a significant prognostic value. In this review, we provide an overview of the role of these biomarkers and their characterization in the management of lung cancer, melanoma, colorectal cancer, gastric cancer, head and neck cancer, renal cell carcinoma, urothelial cancers, and breast cancer.
Identifiants
pubmed: 31683784
pii: ijms20215452
doi: 10.3390/ijms20215452
pmc: PMC6862285
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CTLA-4 Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
Cancer. 1996 Apr 1;77(7):1303-10
pubmed: 8608507
Nat Rev Cancer. 2007 Nov;7(11):834-46
pubmed: 17957189
Cancer Sci. 2018 Feb;109(2):272-278
pubmed: 29247573
Oncoimmunology. 2019 Apr 3;8(7):1593806
pubmed: 31143514
Urology. 2015 Mar;85(3):703.e1-6
pubmed: 25733301
Oncologist. 2019 Jan;24(1):1-3
pubmed: 30352943
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nat Immunol. 2002 Nov;3(11):999-1005
pubmed: 12407407
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Front Oncol. 2018 Jul 06;8:257
pubmed: 30035101
J Clin Oncol. 2016 Sep 10;34(26):3115-6
pubmed: 27458310
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Transl Lung Cancer Res. 2017 Apr;6(2):196-211
pubmed: 28529902
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Immunother Cancer. 2018 May 14;6(1):35
pubmed: 29754585
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cancer Immunol Res. 2014 Jan;2(1):1-8
pubmed: 24778159
Breast Cancer. 2018 Jan;25(1):34-42
pubmed: 28488168
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Nat Rev Urol. 2014 Mar;11(3):153-62
pubmed: 24492433
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Biomed Res Int. 2019 Apr 14;2019:6832909
pubmed: 31111063
BMC Cancer. 2019 Mar 7;19(1):207
pubmed: 30845981
F1000Res. 2018 Nov 21;7:
pubmed: 30519454
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Nat Rev Urol. 2016 Jul;13(7):420-31
pubmed: 27324121
Int J Mol Sci. 2019 Jul 23;20(14):
pubmed: 31340438
Cancer Cell. 2015 Aug 10;28(2):253-69
pubmed: 26267538
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496
pubmed: 27185375
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Adv Anat Pathol. 2019 Jul;26(4):270-279
pubmed: 30932972
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Oncologist. 2017 Jun;22(6):680-693
pubmed: 28507203
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Ther Adv Urol. 2016 Oct;8(5):319-326
pubmed: 27695530
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Clin Oncol. 2013 Dec 1;31(34):4311-8
pubmed: 24145345
J Am Acad Dermatol. 2017 Sep;77(3):534-542
pubmed: 28728868
Immunity. 1994 Sep;1(6):447-56
pubmed: 7895156
Histopathology. 2008 Jan;52(1):108-18
pubmed: 18171422
J Clin Invest. 2015 Sep;125(9):3338-46
pubmed: 26241053
Chin Clin Oncol. 2016 Apr;5(2):21
pubmed: 27121881
N Engl J Med. 2015 Nov 12;373(20):1979
pubmed: 26559583
Crit Rev Oncol Hematol. 2019 Jan;133:25-32
pubmed: 30661655
Semin Cancer Biol. 2008 Dec;18(6):388-96
pubmed: 19013244
Transl Lung Cancer Res. 2018 Dec;7(6):661-667
pubmed: 30505710
J Clin Oncol. 2019 Dec 10;37(35):3392-3400
pubmed: 31513484
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Oncotarget. 2017 Aug 1;8(45):79809-79815
pubmed: 29108362
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
Int J Cancer. 2008 Aug 1;123(3):609-15
pubmed: 18498132
Cancer Sci. 2016 Sep;107(9):1193-7
pubmed: 27297395
J Clin Pathol. 2018 Mar;71(3):267-274
pubmed: 28877959
World J Gastroenterol. 2016 Sep 21;22(35):7926-37
pubmed: 27672288
Clin Sci (Lond). 2017 Oct 27;131(21):2627-2642
pubmed: 29079639
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Drug Des Devel Ther. 2013;7:37-52
pubmed: 23403548
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
Nat Immunol. 2012 Dec;13(12):1129-32
pubmed: 23160205
Diagn Pathol. 2018 Feb 9;13(1):12
pubmed: 29426340
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Cancer Immunol Res. 2016 Nov;4(11):959-967
pubmed: 27671167
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
JNCI Cancer Spectr. 2018 Dec 13;2(4):pky056
pubmed: 31360876
Immunotherapy. 2017 Jan;9(2):115-121
pubmed: 28128709
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Biomed Res Int. 2019 Apr 24;2019:9056417
pubmed: 31179334
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
J Radiat Res. 2016 Sep;57(5):541-547
pubmed: 27242338
J Clin Oncol. 2007 Mar 1;25(7):869-75
pubmed: 17327608
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Annu Rev Immunol. 2011;29:235-71
pubmed: 21219185
Pathol Res Pract. 2018 Aug;214(8):1074-1080
pubmed: 29803657
Ann Surg Oncol. 2018 Nov;25(12):3755-3763
pubmed: 30203407
J Natl Cancer Inst. 2019 Mar 26;:
pubmed: 30912808
J Clin Invest. 2016 Jun 1;126(6):2334-40
pubmed: 27159395
Radiother Oncol. 2012 Sep;104(3):272-8
pubmed: 22938727
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Oncologist. 2019 Dec;24(12):1534-1542
pubmed: 31292272
Br J Cancer. 2018 Jul;119(2):153-159
pubmed: 29955135
J Immunother Cancer. 2017 Nov 21;5(1):94
pubmed: 29157296
J Clin Oncol. 2018 May 10;36(14):1412-1418
pubmed: 29584545
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Clin Oncol. 2013 Nov 10;31(32):e439-42
pubmed: 24043743
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
BioDrugs. 2019 Apr;33(2):159-171
pubmed: 30825132
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Ann Oncol. 2015 Apr;26(4):812-7
pubmed: 25600565
J Clin Oncol. 2017 Dec 20;35(36):4050-4056
pubmed: 28837405
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
World J Gastroenterol. 2016 Jan 14;22(2):557-66
pubmed: 26811607
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
BMC Cancer. 2019 May 17;19(1):467
pubmed: 31101023
Nat Med. 2014 Apr;20(4):344-6
pubmed: 24710378
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Am J Surg Pathol. 2018 Feb;42(2):183-191
pubmed: 28914717
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
Clin Chem. 2014 Jan;60(1):98-110
pubmed: 24170611
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
J Clin Oncol. 2015 Oct 10;33(29):3346-55
pubmed: 26351340
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Cancer. 2012 May 1;118(9):2476-85
pubmed: 21953023
Chin Clin Oncol. 2016 Apr;5(2):22
pubmed: 27121882
Cancer Immunol Immunother. 2008 Jan;57(1):97-106
pubmed: 17602225
Cancers (Basel). 2019 Jul 22;11(7):
pubmed: 31336685
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Clin Cancer Res. 2015 Jul 1;21(13):3052-60
pubmed: 25788491
J Invest Dermatol. 2016 May;136(5):994-1001
pubmed: 26829031
Adv Exp Med Biol. 2017;1026:383-402
pubmed: 29282694
Urol Oncol. 2014 Aug;32(6):791-7
pubmed: 24794251